Viewing by month: November 2014

The FDA has approved the supplemental New Drug Applications for paliperidone palmitate (Invega Sustenna) to treat schizoaffective disorder as either monotherapy or adjunctive therapy.

The FDA has approved the supplemental New Drug Applications for paliperidone palmitate (Invega Sustenna) to treat schizoaffective disorder as either monotherapy or adjunctive therapy. The drug is a once-monthly atypical long-acting antipsychotic produced by Janssen Pharmaceuticals, Inc. Invega Sustena is the first approved once-monthly medication to treat the disorder as monotherapy.

The approval comes following a long-term maintenance study that measured the ability to delay relapse in schizoaffective disorder. The study included a six-month open-label treatment period and a 15-month double-blind period.

http://www.janssencns.com/invegasustenna/sites/www.janssencns.com.invegasustenna/files/pdf/Invega_Sustenna_PI.pdf

0 comments | Posted by Kai Dawn Stauffer LeMasson on Nov 18, 2021 at 4:45 PM | Categories: